Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-11 02:36 | 2023-07-07 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $2.80 | 1,880 | $5,264 | 374,722 | -0.5% |
| 2023-06-10 02:10 | 2023-06-07 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $17.04 | 8,897 | $151,584 | 376,602 | -2.3% |
| 2023-04-11 23:59 | 2023-04-10 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $19.52 | 1,869 | $36,483 | 382,999 | -0.5% |
| 2023-03-23 23:50 | 2023-03-10 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $20.20 | 19,489 | $393,625 | 384,868 | -4.8% |
| 2023-03-11 05:55 | 2023-03-08 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $20.62 | 56,261 | $1,159,972 | 384,868 | -12.8% |
| 2023-01-11 00:46 | 2023-01-06 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $19.95 | 1,538 | $30,683 | 295,483 | -0.5% |
| 2022-12-10 03:19 | 2022-12-08 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $15.79 | 2,543 | $40,154 | 297,020 | -0.8% |
| 2020-06-12 13:59 | 2020-06-10 | FGEN | KYNTRA BIO, INC. | Conterno Enrique A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $35.57 | 27,800 | $988,882 | 27,800 | +100.0% |
| 2019-02-20 23:37 | 2019-02-15 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; SVP&Pres, LillyDiab & LillyUSA | Pharmaceutical Preparations | SALE | $121.00 | 25,000 | $3,025,000 | 132,962 | -15.8% |
| 2018-06-01 23:22 | 2018-05-31 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; SVP&Pres, LillyDiab & LillyUSA | Pharmaceutical Preparations | SALE | $85.00 | 25,000 | $2,125,000 | 124,534 | -16.7% |
| 2017-05-08 22:44 | 2017-05-04 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; SVP&Pres, LillyDiab & LillyUSA | Pharmaceutical Preparations | SALE | $82.76 | 25,000 | $2,069,000 | 114,217 | -18.0% |
| 2015-12-10 22:09 | 2015-12-09 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $83.88 | 25,000 | $2,097,000 | 88,131 | -22.1% |
| 2014-11-04 23:08 | 2014-11-03 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $66.03 | 5,000 | $330,150 | 72,736 | -6.4% |
| 2014-10-03 18:12 | 2014-10-01 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $64.86 | 5,000 | $324,300 | 77,736 | -6.0% |
| 2014-09-03 18:42 | 2014-09-02 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $63.60 | 5,000 | $318,000 | 82,736 | -5.7% |
| 2014-07-28 22:16 | 2014-07-25 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $63.79 | 10,000 | $637,900 | 87,736 | -10.2% |
| 2013-08-16 18:18 | 2013-08-15 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $53.79 | 5,000 | $268,950 | 57,177 | -8.0% |
| 2013-07-15 23:23 | 2013-07-15 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $51.43 | 5,000 | $257,150 | 62,177 | -7.4% |
| 2013-06-18 17:34 | 2013-06-17 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $52.45 | 5,000 | $262,250 | 67,177 | -6.9% |
| 2013-05-16 23:06 | 2013-05-15 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $56.15 | 5,000 | $280,750 | 72,177 | -6.5% |
| 2013-04-16 18:46 | 2013-04-15 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $57.10 | 5,000 | $285,500 | 71,875 | -6.5% |
| 2012-08-01 22:13 | 2012-08-01 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $44.16 | 5,000 | $220,800 | 27,012 | -15.6% |
| 2012-07-03 22:34 | 2012-07-02 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $43.00 | 5,000 | $215,000 | 32,012 | -13.5% |
| 2012-06-04 22:52 | 2012-06-01 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $40.60 | 5,000 | $203,000 | 37,012 | -11.9% |
| 2012-05-02 17:09 | 2012-05-01 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $41.32 | 5,000 | $206,600 | 42,012 | -10.6% |
| 2012-04-04 20:37 | 2012-04-02 | LLY | ELI LILLY & Co | Conterno Enrique A | Officer; Sr. VP & Pres., Lilly Diabetes | Pharmaceutical Preparations | SALE | $40.30 | 5,000 | $201,500 | 47,012 | -9.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.